Table 1.
Baseline HRQL in the all-treated population, assessed by the SGRQ and SF-36 instruments, showing that patients in both groups were similarly impaired at baseline
| Bosentan | Placebo | |
|---|---|---|
| SGRQ, median (95% CI) | ||
| Symptoms components | 51.2a (44.7, 56.0) | 54.8b (47.9, 59.1) |
| Activity components | 59.5c (53.6, 66.1) | 59.5d (56.0, 65.6) |
| Impacts components | 32.9c (25.0, 40.3) | 30.5e (25.7, 38.4) |
| Total score | 43.9f (36.6, 52.1) | 44.3g (40.2, 50.0) |
|
| ||
| SF-36, median (95% CI) | ||
| Physical functioning | 55.0a (40.0, 65.0) | 47.5b (35.0, 55.0) |
| Role – physical | 25.0c (25.0, 50.0) | 25.0e (25.0, 50.0) |
| Bodily pain | 74.0a (64.0, 100.0) | 64.0b (61.0, 74.0) |
| Social functioning | 75.0a (75.0, 87.5) | 81.3b (62.5, 87.5) |
| Mental health | 80.0c (68.0, 84.0) | 76.0b (68.0, 80.0) |
| Role – emotional | 100.0a (66.7, 100.0) | 100.0e (66.7, 100.0) |
| Vitality | 50.0c (40.0, 55.0) | 50.0b (40.0, 55.0) |
| General health | 47.0a (37.0, 57.0) | 46.0b (40.0, 52.0) |
a
n=68
b
n=82
c
n=67
d
n=83
e
n=81
f
n=66
g
n=80
95% CI, 95% confidence interval of the median; HRQL, health-related quality of life; SF-36, 36-item short-form instrument; SGRQ, St George's Respiratory Questionnaire.